ALNYLAM PHARMACEUTICALS INC. financial statements, including revenue, expenses, profit, and loss
The total revenue of DUL for the last quarter is 458.14 M EUR, and it's 15.00% higher compared to the previous quarter. The net income of Q1 24 is -61.11 M EUR.